Trial intelligence / Profile preview

ABL001 versus investigator-selected TKI in newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase

CTR20212945Phase 3Active

Sponsor

Novartis

Start

Feb 2022

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1